Company Profile (AI Text)
Name: SenoGuard
Canonical URL: https://wefunder.com/senoguard.inc
Updated at: 2026-06-12T03:31:22Z

Tagline: Non-Radiation Breakthrough in Breast Cancer Treatment

Key claims:
- Total raised on Wefunder: 54400 | citation: https://wefunder.com/senoguard.inc#claim-total-raised
- Total investors: 22 | citation: https://wefunder.com/senoguard.inc#claim-total-investors

Verified facts:
- Total raised on Wefunder: 54400 | observed_at: 2026-06-12T03:31:22Z | expires_at: 2026-06-13T03:31:22Z
- Total investors: 22 | observed_at: 2026-06-12T03:31:22Z | expires_at: 2026-06-13T03:31:22Z

Computed metrics:
- total_amount_raised: 54400
- total_investors: 22
- team_size: 5
- featured_investor_count: 1
- faq_count: 2
- recent_post_count: 2

Quick facts:
- An alternative to radiation after lumpectomy that avoids pain, fatigue,clinical and cosmetic damage. | citation: https://wefunder.com/senoguard.inc#claim-fact-1
- $1.2M from National Science Foundation: proved effectiveness. 2nd grant awarded to do FDA submission | citation: https://wefunder.com/senoguard.inc#claim-fact-2
- Affordable & accessible, avoids RT toxicities, offers a better option. Done at time of lumpectomy | citation: https://wefunder.com/senoguard.inc#claim-fact-3
- Experienced team with 100+ years in advancing women's healthcare with innovative medical devices. | citation: https://wefunder.com/senoguard.inc#claim-fact-4
- Eliminates up to 6 weeks of daily treatments at radiation center that may require long distances | citation: https://wefunder.com/senoguard.inc#claim-fact-5
- Allows proper treatment for 28% of patients unable to get RT due to distance, cost, or no time off. | citation: https://wefunder.com/senoguard.inc#claim-fact-6
- Allows breast cancer treatment to be done at community hospitals where most women prefer treatment. | citation: https://wefunder.com/senoguard.inc#claim-fact-7
- Allows lumpectomy to be performed globally in countries where mastectomy is currently only choice | citation: https://wefunder.com/senoguard.inc#claim-fact-8

FAQ:
- Q: Hi, I'm Sherwood Neiss, managing partner of D3VC.ai. We are an early-stage venture fund that invests in select RegCF offerings. Your offering scored high on our algorithm, and we had an opportunity to begin diligence on your company. During our investment committee call, the f...
  A: Hi Sherwood, Thanks for inquiring about SenoGuard. Answers to your very good questions follow. It appears that you are comparing SenoGuard’s more precise targeting to whole breast radiation; the first form of radiation used to eliminate residual cancer cells after lumpectomy that was developed almost 40 years ago and still widely used today. Since then, it has been proven that Up to 90% of local recurrences originate in the 1cm area of tissue surrounding the surgical cavity. While whole breas...
- Q: Have there been animal studies to date to verify this procedure? Would it be possible to offer this as a veterenary treatment and monitor outcomes? I can't imagine that anyone would subject their pet to radiation treatments.
  A: Steve, Yes, we have done animal studies. SenoGuard actually looked at the veterinary market as an initial entry point into human procedures. And although the vet market is growing, it is still a very small market and thus not attractive to investors. Cryoablation for surface and subdermal lumps and bumps have been in use with vets for awhile quite successfully but to suggest deeper or internal organ tumors would require a much stronger cryoablation technology (like that of SenoGuard) but its ...

Recent posts:
- Novel Breast Cancer Treatment being Researched by SenoGuard (2025-02-18T14:59:43Z) https://wefunder.com/feed/179606
- SenoGuard receives 2nd National Science Foundation Award (2025-01-21T17:31:38Z) https://wefunder.com/feed/178884